With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. Late Thursday, PTC revealed that it ...
The FDA stated that ataluren data lacked the substantial evidence of effectiveness needed for approval, leading PTC Therapeutics to withdraw its NDA. Following discussions with the Food and Drug ...
Sifting through countless of stocks in the Software industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...
PTC releases Codebeamer 3.2, Codebeamer AI 1.0, and Pure Variants 7.2 Codebeamer 3.2 and Pure Variants 7.2 strengthen product data foundation for regulated, software-driven product development, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results